Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Worse Outcomes After Esophagectomy at Private Equity-Owned Hospitals

2.

How AI will transform mental health support for patients with breast cancer

3.

'It's rare and it's scary.' Dark spot on your fingernail could mean cancer

4.

In heavily pretreated DLBCL, Triplet Scores a Survival Victory.

5.

Breast cancer prevention: How nurse practitioners and physician assistants can help


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot